Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 4, 2014
Efficacy and safety of delayed-release dimethyl fumarate in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS)Ralf Gold, Gavin Giovannoni, J Theodore Phillips, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|November 8, 2014
Anti-JC Virus Antibody Prevalence in Canadian MS PatientsVirender Bhan, Yves Lapierre, Mark S Freedman, et al.
Journal of Neurology|January 8, 2013
Clinical effects of natalizumab on multiple sclerosis appear early in treatment courseLudwig Kappos, Paul W O'Connor, Christopher H Polman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 18, 2014
Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme resultsHelmut Butzkueven, Ludwig Kappos, Fabio Pellegrini, et al.
Frontiers in Molecular Neuroscience|October 23, 2023
Type 2 cytokines sensitize human sensory neurons to itch-associated stimuliMadison R Mack, Yannick Miron, Fanny Chen, et al.
Current Medical Research and Opinion|October 14, 2016
Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosisRobert J Fox, Andrew Chan, Annie Zhang, et al.
Journal of the Neurological Sciences|April 24, 2012
Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MSLaura J Balcer, Steven L Galetta, Chris H Polman, et al.
American Journal of Clinical Dermatology|June 10, 2023
Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III TrialElaine C Siegfried, Michael J Cork, Norito Katoh, et al.
BMJ Open|March 27, 2020
Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodologyAmy S Paller, Emma Guttman-Yassky, Alan D Irvine, et al.
Paediatric Drugs|January 24, 2024
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic DermatitisAmy S Paller, Elaine C Siegfried, Michael J Cork, et al.
Pageof 6